Category: carbodipa/levodopa

  • Sublingual Apomorphine (Kynmobi) for Parkinson’s Disease

    Date:  October 19, 2020 Issue #:  1609 Summary:  The FDA has approved a sublingual fi lm formulation of the nonergot dopamine agonist apomorphine (Kynmobi – Sunovion) for acute, intermittent treatment of “off” episodes in patients with Parkinson’s disease (PD). A subcutaneous formulation of apomorphine (Apokyn) has been available for years for the same indication in […]